Clinical trial · Interventional
SNV1521 in Participants With Advanced Solid Tumors
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors
NCT06220864CI-TRIAL-00115922recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Abiraterone | Drug | Abiraterone | ALIAS |
| Darolutamide | Drug | Darolutamide | ALIAS |
| DB-1310 | Drug | — | UNRESOLVED |
| SNV1521 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (10)
- type
- EXPERIMENTAL
- label
- Monotherapy Dose Escalation
- interventionNames
- Drug: SNV1521
- type
- EXPERIMENTAL
- label
- Monotherapy Dose Expansion
- interventionNames
- Drug: SNV1521
- type
- EXPERIMENTAL
- label
- Combination Dose Escalation
- interventionNames
- Drug: SNV1521
- Drug: DB-1310
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced or metastatic solid tumor malignancy * Evaluable or Measurable disease (RECIST 1.1 Criteria). * ECOG Performance Status 0 or 1. * Life expectancy \> 3 months Exclusion Criteria: * History of other malignancy within the past 2 years * Prior diagnosis of Myelodysplastic syndrome or Acute Myeloid Leukemia * Significant cardiovascular disease within 6 months * Significant gastrointestinal disease * HIV infection with a CD4+ T-cell count \< 200 cells/μL and/or a detectable viral load * Liver dysfunction
References
Publications (0)
Data not yet available
No reference posted for this study.